

INTRODUCTION	xvi
STUDY GOALS AND OBJECTIVES.....	xvi
REASONS FOR DOING THIS STUDY	xvi
CONTRIBUTIONS TO THE STUDY AND FOR WHOM.....	xvi
SCOPE AND FORMAT	xvii
METHODOLOGY	xvii
INFORMATION SOURCES.....	xvii
ANALYST CREDENTIALS.....	xviii
RELATED BCC REPORTS	xviii
BCC ONLINE SERVICES.....	xviii
DISCLAIMER	xviii
SUMMARY.....	xix
<i>SUMMARY TABLE GLOBAL MARKET FORECAST FOR ANTIFUNGAL</i>	
<i>AGENTS, THROUGH 2012 (\$ MILLIONS)</i>	XX
<i>SUMMARY FIGURE GLOBAL ANTIFUNGAL AGENT SALES BY</i>	
<i>MARKET SEGMENT, 2005 AND 2012 (%)</i>	XXI
OVERVIEW	1
HISTORY AND CURRENT STATE OF ANTIMICROBIALS	1
<i>TABLE 1 DEATHS ATTRIBUTABLE TO MICROBIOLOGIC</i>	
<i>PATHOGENS IN HISTORY</i>	2
TYPES OF ANTIMICROBIALS.....	2
BACTERIA	3
VIRUSES	3
PROTOZOA	4
FUNGI	4
DEFINITION OF THE INDUSTRY	5
CONCEPTS IN THE INDUSTRY.....	6
IMPORTANCE OF THE INDUSTRY.....	6
PRODUCT LIFE CYCLES	7
<i>TABLE 2 DRUG DEVELOPMENT LIFECYCLE FOLLOWING</i>	
<i>DISCOVERY OF NEW DRUG</i>	8
DEVELOPMENT OF ANTIFUNGALS	8
FUTURE DEVELOPMENTS	9
2006 NEW DRUG ACTIVITY.....	9
2005 NEW DRUG ACTIVITY.....	10
WITH AN EYE TOWARD THE FUTURE.....	11
TYPE OF APPLICATIONS: HUMAN HEALTHCARE, VETERINARY,	
AGRICULTURE, AND ENVIRONMENTAL.....	12
TYPE OF APPLICATIONS: HUMAN HEALTHCARE	12
HUMAN FUNGAL INFECTIONS	13
RISK FACTORS FOR DEVELOPING FUNGAL INFECTIONS.....	13

<i>TABLE 3 RISK FACTORS ASSOCIATED WITH HUMAN FUNGAL INFECTIONS</i>	13
CANDIDIASIS.....	14
Cutaneous Candidiasis.....	15
Chronic Mucocutaneous Candidiasis.....	15
GI Tract Candidiasis.....	15
Respiratory Tract Candidiasis.....	15
Genitourinary Tract Candidiasis.....	15
Hepatosplenic Candidiasis.....	16
Systemic Candidiasis.....	16
Candidemia.....	16
Disseminated Candidiasis.....	17
ASPERGILLOSIS.....	18
BLASTOMYCOSIS.....	18
COCCIDIOIDOMYCOSIS.....	19
CRYPTOCOCCOSIS.....	19
DERMATOPHYTOSIS.....	20
HISTOPLASMOSIS.....	20
ONYCHOMYCOSIS.....	21
PARACOCCIDIOIDOMYCOSIS.....	22
PSEUDALLESCHERIASIS.....	23
SPOROTRICHOSIS.....	23
ZYGOMYCOSIS.....	24
<i>TABLE 4 INCIDENCE OF COMMON FUNGAL DISEASES</i>	25
HUMAN ANTIFUNGAL AGENTS.....	26
<i>TABLE 5 GLOBAL MARKET FORECAST FOR HUMAN ANTIFUNGAL CONSUMPTION BY PRODUCT TYPE, THROUGH 2012 (\$ MILLIONS)</i>	26
ECHINOCANDINS.....	26
ANTIMETABOLITES.....	26
AZOLES.....	27
POLYENES.....	27
OTHER.....	27
<i>TABLE 6 ANTIFUNGAL PHARMACEUTICAL SALES: TRIAZOLES VS. OTHERS THROUGH 2009 (\$ MILLIONS)</i>	28
<i>TABLE 7 PHARMACEUTICAL ANTIFUNGALS BY CLASS/MECHANISM OF ACTION (%)</i>	28
<i>FIGURE 1 PERCENTAGE ANTIFUNGALS BY CLASS/MECHANISM OF ACTION (%)</i>	29
<i>TABLE 8 MAJOR ANTIFUNGAL AGENTS BY CLASS AND AVERAGE SALES PRICE PER DOSAGE</i>	30
<i>TABLE 9 FUNGAL INFECTION AND TRADITIONAL PHARMACEUTICAL REMEDY</i>	31

<i>TABLE 10 TYPE OF CANDIDAL INFECTION AND PHARMACEUTICAL TREATMENT</i>	32
SIDE EFFECTS	32
<i>TABLE 11 LIFE THREATENING SIDE EFFECTS FROM ANTIFUNGAL PHARMACEUTICALS</i>	33
OVER THE COUNTER ANTIFUNGAL PREPARATIONS.....	33
<i>TABLE 12 COMMON FUNGAL INFECTIONS AND OTC ROUTES OF ADMINISTRATION</i>	34
NATURAL ANTIFUNGAL COMPLEXES.....	35
Herbal Antifungal Agents	35
<i>TABLE 13 COMMON HERBAL ANTIFUNGALS</i>	36
Enzyme-Based Antifungal Agents.....	36
<i>TABLE 14 COMMON ENZYMES USED IN NATURAL ANTIFUNGAL PRODUCTS</i>	36
Homeopathic Antifungal Agents.....	37
LABORATORY TESTING AND HISTOPATHOLOGY FOR FUNGAL INFECTIONS IN HUMANS.....	37
SPECIMEN EXAMINATION	37
CULTURES	37
BLOOD SEROLOGY.....	37
ALTERNATIVE HEALTHCARE APPROACHES TO TESTING AND DIAGNOSIS OF FUNGAL INFECTIONS	38
CAM TESTING AND SPECIALIZED LABORATORIES	38
QUESTIONNAIRE FOR SYMPTOMS.....	39
FUNGAL RESISTANCE	39
<i>TABLE 15 COMMON REASONS FOR FUNGAL RESISTANCE</i>	40
STRATEGIES TO IMPROVE RESPONSE AND DECREASE MORTALITY	40
VETERINARY ANTIFUNGAL SEGMENT	41
THE INDUSTRY.....	41
VETERINARY FUNGAL INFECTIONS	41
ASPERGILLOSIS.....	41
CANDIDIASIS.....	41
COCCIDIOIDOMYCOSIS	42
CRYPTOCOCCOSIS.....	42
EPIZOOTIC LYMPHANGITIS UNIQUE TO HORSES.....	42
GEOTRICHOSIS.....	43
HISTOPLASMOSIS	43
HYALOPHYPHOMYCOSIS.....	43
MYCETOMAS	43
NORTH AMERICAN BLASTOMYCOSIS	43
OOMYCOSIS	44
PAECILOMYCOSIS.....	44
PENNICILLIOSIS	44

PHAEOHYPHOMYCOSIS.....	44
RHINOSPORIDIOSIS.....	45
SPOROTRICHOSIS	45
ZYGOMYCOSIS	45
VETERINARY ANTIFUNGAL AGENTS.....	45
POLYENES	45
AZOLES.....	45
ANTIMETABOLITES	46
OTHER	46
Griseofulvin.....	46
Lufenuron	46
<i>TABLE 16 VETERINARY FUNGAL INFECTIONS AND PHARMACEUTICAL OPTIONS</i>	<i>46</i>
<i>TABLE 16 (CONTINUED).....</i>	<i>47</i>
<i>TABLE 17 COMMON SIDE EFFECTS FROM VETERINARY ANTIFUNGALS.....</i>	<i>48</i>
VETERINARY BASED LABORATORY TESTS AND HISTOLOGY	48
AGRICULTURAL ANTIFUNGAL SEGMENT.....	49
THE INDUSTRY.....	49
GOVERNMENT REGULATIONS	50
AGRICULTURE ANTIFUNGALS: MECHANISMS OF ACTION	50
AGRICULTURAL PRODUCTS AND APPLICATIONS.....	51
<i>TABLE 18 AGRICULTURAL ANTIFUNGAL ACTIVE INGREDIENTS WITH ≥100,000 LBS APPLIED, 2002.....</i>	<i>51</i>
<i>TABLE 18 (CONTINUED).....</i>	<i>52</i>
<i>TABLE 19 ANTIFUNGAL USE BY REGION OF THE UNITED STATES, 2002</i>	<i>52</i>
<i>TABLE 20 ANTIFUNGAL USE BY CROP TYPE, 2002.....</i>	<i>53</i>
AGRICULTURAL SIDE EFFECTS	53
<i>TABLE 21 SIDE EFFECTS FROM COMMON AGRICULTURAL ANTIFUNGAL AGENTS.....</i>	<i>54</i>
<i>TABLE 21 (CONTINUED).....</i>	<i>55</i>
AGRICULTURAL FUNGAL RESISTANCE	55
STRATEGIES TO PREVENT FUNGAL RESISTANCE IN AGRICULTURAL FUNGI.....	56
ENVIRONMENTAL ANTIFUNGAL SEGMENT.....	57
THE INDUSTRY.....	57
WHY ENVIRONMENTAL MOULD IS A UNIQUE PROBLEM.....	58
COMMON ENVIRONMENTAL MOULDS	58
ALTERNARIA	58
ASPERGILLUS	58
CLADOSPORIUM.....	58

PENICILLIUM.....	59
HEALTH RISKS DUE TO ENVIRONMENTAL FUNGI AND MOULD	59
TABLE 22 COMMON HEALTH SYMPTOMS BASED ON ENVIRONMENTAL FUNGI AND MOULDS	60
TABLE 23 RISK FACTORS ASSOCIATION WITH ENVIRONMENTAL MOULD REACTIONS.....	60
TABLE 24 COMMON SOURCE LOCATIONS FOR ENVIRONMENTAL MOULDS.....	61
GOVERNMENT REGULATORY AGENCIES AND PROFESSIONAL ASSOCIATIONS	62
GOVERNMENT REGULATIONS	62
FOOD AND DRUG ADMINISTRATION.....	62
TABLE 25 ANTIFUNGAL WARNING LETTERS FOR THE HUMAN SEGMENT FROM THE FDA 1997–2006.....	63
TABLE 25 (CONTINUED).....	64
ENVIRONMENTAL PROTECTION AGENCY (EPA)	64
UNITED STATES DEPARTMENT OF AGRICULTURE (USDA)	65
FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS	66
PROFESSIONAL ASSOCIATIONS.....	66
MEDICAL AND VETERINARY ASSOCIATIONS.....	66
AGRICULTURAL ASSOCIATIONS	66
OTHER ENVIRONMENTAL ASSOCIATIONS	67
MAJOR ANTIFUNGAL MANUFACTURERS	68
HUMAN HEALTHCARE	68
PHARMACEUTICAL MANUFACTURERS	68
TABLE 26 MAJOR ANTIFUNGAL HUMAN PHARMACEUTICAL MANUFACTURERS.....	68
TABLE 26 (CONTINUED).....	69
FIGURE 2 PERCENTAGE OF ANTIFUNGAL PHARMACEUTICAL MANUFACTURERS BY COUNTRY.....	69
TABLE 27 MAJOR PHARMACEUTICAL ANTIFUNGAL MANUFACTURERS, 2006 (\$ MILLION).....	70
MAJOR PHARMACEUTICAL MANUFACTURER PROFILES	70
Astellas.....	70
Barrier Therapeutics	71
Enzon Pharmaceuticals.....	71
Gilead Sciences, Inc.....	71
Medicis	71
Teva Pharmaceutical USA	71
Novartis.....	72
Pfizer, Inc.....	72

Schering-Plough Corp.....	72
SciClone Pharmaceuticals, Inc.....	72
Taro Pharmaceutical Industries, Ltd.	73
York Pharma.....	73
MAJOR OTC ANTIFUNGAL MANUFACTURERS	73
PHARMACEUTICAL OTC MARKET.....	74
<i>TABLE 28 MAJOR HUMAN OTC ANTIFUNGAL MANUFACTURERS</i>	
<i>AND PRODUCTS</i>	74
PHARMACEUTICAL-BASED OTC MANUFACTURER	
PROFILES.....	75
Alva-Amco Pharmacal	75
Blaine Labs	75
Dartmouth Pharmaceuticals.....	75
Del Laboratories	75
Dermik	75
Ganeden Biotech.....	76
McNeil Consumer and Specialty Pharmaceuticals.....	76
Kramer Laboratories	76
Novartis.....	76
Pedinol Pharmacal.....	76
Pfizer	77
Schering-Plough.....	77
Stiefel Laboratories	77
Tarmac Products.....	77
ALTERNATIVE OTC MARKET.....	77
<i>TABLE 29 COMMONLY AVAILABLE ALTERNATIVE ANTIFUNGALS</i>	78
ProSymbiotics	78
Nature's Plus	78
Aqua Flora	79
NOW Foods	79
Rainbow Light.....	79
Enzymedica.....	80
Pure Essence Laboratories.....	80
Michael's Naturopathic Programs	80
Renew Life	80
Garden of Life	81
Nutrition Now.....	81
Solaray	81
Vitanica.....	82
Forest Herbs Research	82
Crystal Star Herbal Nutrition	82
VETERINARY MARKET	82
<i>TABLE 30 MAJOR VETERINARY ANTIFUNGAL PHARMACEUTICAL</i>	
<i>MANUFACTURERS AND PRODUCTS</i>	83

<i>TABLE 30 (CONTINUED)</i>	84
<i>FIGURE 3 PERCENTAGE OF MANUFACTURERS OF VETERINARY ANTIFUNGALS BY COUNTRY (%)</i>	84
MAJOR VETERINARY ANTIFUNGAL MANUFACTURER PROFILES.....	85
Argent	85
Bioniche Life Science	85
Butler Animal Health.....	85
Durvet Animal Health Products	85
Med-Pharmex.....	86
Virbac	86
Schering-Plough Animal Health	86
Stiefel	86
Vetoquinol	86
Vedco	87
Wyeth Animal Health.....	87
AGRICULTURAL ANTIFUNGAL MANUFACTURERS	87
<i>TABLE 31 MAJOR AGRICULTURAL ANTIFUNGAL MANUFACTURERS</i>	88
<i>FIGURE 4 PERCENT AGRICULTURAL ANTIFUNGAL MANUFACTURERS BY COUNTRY (%)</i>	89
MAJOR AGRICULTURAL MANUFACTURER PROFILES	89
AgriChem	89
AgraQuest	90
Albaugh, Inc.....	90
American Vanguard	90
Arysta Life Sciences	90
BASF	91
Bayer CropScience.....	91
Makhteshim Agan of North America, Inc.	92
Cerexagri.....	92
Chemtura	92
Dow AgroSciences.....	93
DuPont Crop Protection	93
Gowan	93
JH Biotech.....	94
Helena Chemical Company	94
Nordox AS	94
Nufarm	95
Syngenta	95
Valent.....	95
ANTIFUNGAL INDUSTRY	96
ANTIFUNGAL MARKET TRENDS: HUMAN HEALTHCARE	96
ACCELERATING ANTIFUNGAL DRUG DEVELOPMENT	96

<i>TABLE 32 PHARMACEUTICAL ANTIFUNGAL PRODUCTS IN THE PIPELINE, 2006</i>	97
<i>TABLE 33 NEW PRESCRIPTION ANTIFUNGALS, 2005–2006</i>	98
INCREASED TYPES OF TESTING	99
Need to Increase Use and Acceptance of Newer Drugs	99
Trends in Class Used and Administration Method.....	100
<i>TABLE 34 PHARMACEUTICAL ANTIFUNGALS BY ADMINISTRATION TYPE (%)</i>	101
<i>FIGURE 5 PERCENTAGE OF PHARMACEUTICAL ANTIFUNGAL PRODUCTS BY ADMINISTRATION TYPE (%)</i>	101
<i>TABLE 35 GLOBAL MARKET FORECAST FOR ANTIFUNGAL PHARMACEUTICAL PRODUCTS BY ADMINISTRATION, THROUGH 2012 (\$ MILLIONS)</i>	102
UTILIZATION OF OTC AND NATURAL/ALTERNATIVE ANTIFUNGAL AGENTS.....	102
Shifting Market from Prescription to OTC.....	102
<i>TABLE 36 COMPANIES WITH PRODUCTS SHIFTING FROM PRESCRIPTION ANTIFUNGALS TO OTC STATUS</i>	103
<i>TABLE 37 SALES SHIFT FROM PHARMACEUTICAL TO OTC, 2005 (\$ MILLIONS)</i>	103
Market Demand for OTC Products.....	103
ANTIFUNGAL MARKET TRENDS: VETERINARY HEALTH.....	104
ANTIFUNGAL MARKET TRENDS—AGRICULTURAL.....	105
DECREASE IN NUMBER OF MANUFACTURERS	105
DECREASE IN PRICE PER POUND OF SYNTHETIC AGENTS.....	105
INCREASED PRODUCTION AND DISTRIBUTION OF GENERICS.....	106
INCREASE IN FUNGAL RESISTANCE IN PHYTOMYCOTIC ORGANISMS	106
PATENT ANALYSIS.....	107
PURPOSE OF A PATENT ANALYSIS.....	107
DUE CARE IN REVIEWING THE PATENT ANALYSIS.....	107
NEW ANTIFUNGAL PATENTS ISSUED.....	108
<i>TABLE 38 ANTIFUNGAL PATENT TRENDS, 1990–2006</i>	108
<i>TABLE 38 (CONTINUED)</i>	109
<i>FIGURE 6 ANTIFUNGAL PATENT TRENDS, 1990–2006</i>	109
<i>TABLE 39 PATENT BY ANTIFUNGAL MARKET SEGMENT</i>	110
1990–2006.....	110
<i>TABLE 40 NEW ANTIFUNGAL PATENTS ISSUED, 2005–2006</i>	110
<i>TABLE 40 (CONTINUED)</i>	111
<i>TABLE 40 (CONTINUED)</i>	112
<i>TABLE 40 (CONTINUED)</i>	113

<i>TABLE 41 ASSIGNEES OF THREE OR MORE PATENTS FOR ANTIFUNGAL PRODUCTS, 2005–2006</i>	114
<i>TABLE 42 PATENT TRENDS BY COUNTRY, 2005–2006</i>	114
<i>FIGURE 7 NEW ANTIFUNGAL PATENT APPROVALS BY COUNTRY, 2005–2006 (%)</i>	115
<i>TRENDS IN PATENT APPLICATIONS</i>	115
<i>TABLE 43 PATENT APPLICATION TRENDS, 2001–2006</i>	116
<i>FIGURE 8 ANTIFUNGAL PATENT APPLICATIONS BY YEAR, 2001– 2006 (%)</i>	116
<i>TABLE 44 PATENT APPLICATIONS BY ANTIFUNGAL SEGMENT, 2001–2006</i>	117
<i>FIGURE 9 PERCENTAGE OF PATENT APPLICATIONS BY ANTIFUNGAL MARKET SEGMENT, 2001–2006 (%)</i>	117
<i>TABLE 45 NEW PATENT APPLICATIONS, 2005–2006</i>	118
<i>TABLE 45 (CONTINUED)</i>	119
<i>TABLE 45 (CONTINUED)</i>	120
<i>TABLE 46 RECENT TRENDS IN PATENT APPLICATIONS FOR ANTIFUNGALS BY MARKET SEGMENT, 2005–2006</i>	120
<i>TABLE 47 PATENT APPLICATION TRENDS BY COUNTRY, 2005– 2006</i>	121
<i>FIGURE 10 ANTIFUNGAL PATENT APPLICATIONS BY COUNTRY, 2005–2006 (%)</i>	121
<i>PATENT EXPIRATIONS</i>	122
<i>TABLE 48 PATENT EXPIRATIONS, 2006–2011</i>	122
APPENDIX	123
<i>TABLE 49 PHARMACEUTICAL COMPANIES</i>	123
<i>TABLE 49 (CONTINUED)</i>	124
<i>TABLE 49 (CONTINUED)</i>	125
<i>TABLE 49 (CONTINUED)</i>	126
<i>TABLE 49 (CONTINUED)</i>	127
<i>TABLE 49 (CONTINUED)</i>	128
<i>TABLE 49 (CONTINUED)</i>	129
<i>TABLE 49 (CONTINUED)</i>	130
<i>TABLE 49 (CONTINUED)</i>	131
<i>TABLE 49 (CONTINUED)</i>	132
<i>TABLE 49 (CONTINUED)</i>	133